U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839703) titled 'International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma' on Feb. 17.
Brief Summary: The goal of the study is to investigate the feasibility, toxicity, and biological activity of the treatment with dinutuximab beta in combination with standard chemotherapy in EWS to give high-risk patients with a GD2 positiv pumor a benefit in treatment. Within the study is tested with three different dosages in a 3+3 design with three pre-defined dose levels.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
High-risk GD2-Positive Ewing Sarcoma
Intervention:
DRUG: Dinutuximab beta
Dinutuximab b...